Data / Drug companies / Jubilant Cadista Pharmaceuticals Inc.
Jubilant Cadista Pharmaceuticals Inc.: 82 products in the FDA NDC directory, labeler code 59746
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Jubilant Cadista Pharmaceuticals Inc. (labeler code 59746) lists 82 products in the FDA National Drug Code Directory, covering 24 finished drugs by generic name. By type: 81 prescription drugs, 1 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 1, 2026.
The request: Watch Jubilant Cadista Pharmaceuticals Inc. (FDA labeler code 59746): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 59746
- Products in commercial distribution
- 82
- Packages
- 223
- Finished drugs by generic name
- 24
- Prescription products
- 81
- Over the counter products
- 0
- Flagged as original packager
- 73 of 73 products that carry the flag
- Started marketing in the last 12 months
- 10
- Earliest marketing start
- March 1, 1998
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 81 | 98.8% |
| Drugs for further processing | 1 | 1.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 81 | 98.8% |
| Drugs for further processing | 1 | 1.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 34 | 41.5% |
| Tablet, film coated | 24 | 29.3% |
| Tablet, orally disintegrating | 11 | 13.4% |
| Capsule | 6 | 7.3% |
| Capsule, gelatin coated | 3 | 3.7% |
| Tablet, extended release | 3 | 3.7% |
| Tablet, delayed release | 1 | 1.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sildenafil | 59746-436 | Tablet, film coated | Generic drugs (ANDA) | September 1, 2026 |
| Sildenafil | 59746-435 | Tablet, film coated | Generic drugs (ANDA) | September 1, 2026 |
| Sildenafil | 59746-434 | Tablet, film coated | Generic drugs (ANDA) | September 1, 2026 |
| Valsartan | 59746-393 | Tablet | Generic drugs (ANDA) | August 24, 2026 |
| Eslicarbazepine Acetate | 59746-720 | Tablet | Generic drugs (ANDA) | May 1, 2026 |
| Eslicarbazepine Acetate | 59746-719 | Tablet | Generic drugs (ANDA) | May 1, 2026 |
| Eslicarbazepine Acetate | 59746-718 | Tablet | Generic drugs (ANDA) | May 1, 2026 |
| Eslicarbazepine Acetate | 59746-717 | Tablet | Generic drugs (ANDA) | May 1, 2026 |
| Roflumilast | 59746-802 | Tablet | Generic drugs (ANDA) | February 2, 2026 |
| Roflumilast | 59746-801 | Tablet | Generic drugs (ANDA) | February 2, 2026 |
| Risperidone | 59746-226 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Risperidone | 59746-225 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Risperidone | 59746-224 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Risperidone | 59746-223 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Risperidone | 59746-222 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Risperidone | 59746-221 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Tacrolimus | 59746-800 | Capsule, gelatin coated | Generic drugs (ANDA) | November 30, 2024 |
| Tacrolimus | 59746-799 | Capsule, gelatin coated | Generic drugs (ANDA) | November 30, 2024 |
| Tacrolimus | 59746-798 | Capsule, gelatin coated | Generic drugs (ANDA) | November 30, 2024 |
| Sildenafil | 59746-471 | Tablet, film coated | Generic drugs (ANDA) | August 26, 2024 |
| Escitalopram | 59746-281 | Tablet, film coated | Generic drugs (ANDA) | January 1, 2024 |
| Escitalopram | 59746-279 | Tablet, film coated | Generic drugs (ANDA) | January 1, 2024 |
| Escitalopram | 59746-280 | Tablet, film coated | Generic drugs (ANDA) | December 1, 2023 |
| Methenamine Hippurate | 59746-797 | Tablet | Generic drugs (ANDA) | January 24, 2023 |
| Carbamazepine | 59746-791 | Tablet, extended release | Generic drugs (ANDA) | August 20, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.